The first installment lays the foundation for understanding how CAR T works. This second piece delves into the use of CAR T to treat B cell cancers.

BEING OVERWEIGHT OR OBESE IS ASSOCIATED with a higher risk of more than a dozen cancers.

This is a series on the advances in CAR T, a remarkable immunotherapy treatment dubbed a “living drug.” This new therapy genetically modifies a patient’s cells to fight cancer, but current research efforts hope to treat autoimmune diseases, organ damage and more.

Increasing evidence suggests an interplay between the gut microbiome and nonalcoholic fatty liver disease (NAFLD). The role of the microbiome in the early detection of the condition remains unclear.